Dr. Shao-Lee Lin discusses the new data presented at the EULAR 2019 that point to the systemic implications of uncontrolled gout & the need for treatment improvement.
Shao-Lee Lin, M.D., Ph.D., is an internationally known expert and executive in pharmaceutical research and development and a leader of culture change designed to foster robust innovation at all stages of drug development. She is Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Therapeutics, where she is building a world class R&D organization. An accomplished physician/scientist with over 20 years of academic and clinical research experience, Dr. Lin has led teams across multiple therapeutic areas in roles of increasing responsibility at AbbVie, Gilead and Amgen. Dr. Lin is a magna cum laude graduate of Rice University with a bachelor’s degree in biochemistry and chemical engineering. She received her M.D. and Ph.D. at the Johns Hopkins University School of Medicine and held postdoc fellowships in Rheumatology, Allergy, and Immunology at UCSD and The Scripps Clinic and Research Institute. Throughout her career, Dr. Lin has maintained clinical contact and teaching, first as Clinical Scholar at The Rockefeller University and adjunct faculty in Medicine at Cornell, and subsequently at UCLA, Stanford, and, most recently, Northwestern. Results of her research achievement have appeared in leading medical publications on rheumatology, immunology and respiratory topics, among others. Dr. Lin is a strong advocate of the values of collaboration, innovation, and excellence to advance medical science and serve patients by targeting unmet medical needs. Her career-long focus on putting patients first inspires Dr. Lin to develop innovative approaches that speed the development of life-changing drug therapies.